Collegium Pharmaceutical, Inc (COLL) stock

COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value

$24.95+0.14 (+0.56%)

Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –

Collegium Pharmaceutical total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

For fiscal 2015 it was $2.67M.

Period	Period end	Value	Change
FY2015	Dec 31, 2015	$2.67M	–

Parsed from the XBRL in Collegium Pharmaceutical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is COLL.

Revenue growth7.7% · median 25.9%

Gross margin59.0% · median 82.3%

Operating margin15.2% · median 10.2%

Net margin4.7% · median 11.2%

Advertisement
300 × 250

See a number that looks wrong?